肾移植后复发性原发性肾小球肾炎认识的最新进展
复发性肾小球肾炎(GN)是移植肾失功的重要原因,约15%的死亡删失移植肾失功由复发性GN导致,但这一比例可能低估了实际规模。总体而言,18%至22%的移植肾因GN(复发性或推测的新发)而丢失。本文综述原发性GN发病机制、移植肾复发风险及对移植肾存活影响的最新认识,聚焦局灶节段性肾小球硬化、膜性肾病、膜增生性肾小球肾炎和IgA肾病。
要点
- 约15%的死亡删失移植肾失功由复发性GN导致,但可能低估实际问题规模。
- 总体18%至22%的移植肾因GN(复发性或推测的新发)而丢失。
- 移植前充分明确GN特征至关重要,可指导移植后管理。
核心结论
- 对原发性GN发病机制的新认识已对移植产生直接临床影响,有助于更好识别高复发风险候选者并更早诊断,预期将带来治疗乃至预防GN复发的显著改善。
- 移植前充分明确GN特征比以往任何时候都更为重要,该信息将指导移植后管理。
- 复发性GN相对罕见,决定了需要多中心研究来评估、检验和验证最新进展与疗法。
研究设计与样本
- 综述,聚焦对原发性GN病理生理、移植肾复发风险及移植肾存活后果的最新认识。
主要发现
- 约15%的死亡删失移植肾失功由复发性GN导致,但这一发生率可能低估了问题的严重程度。
- 总体18%至22%的移植肾因GN(复发性或推测的新发)而丢失。
- 自肾移植最早时期起就已认识到复发性GN对移植肾存活的影响,但该领域进展缓慢,对GN复发的认识仍有限,很大程度上由于对这些疾病发病机制的理解不完整。
- 综述具体聚焦于最常见的原发性GN类型,包括局灶节段性肾小球硬化、膜性肾病、膜增生性肾小球肾炎和IgA肾病。
临床怎么用
- 移植前充分明确GN特征至关重要,该信息将指导移植后管理。
局限性
- 该领域进展缓慢,对GN复发的认识仍有限,很大程度上由于对这些疾病发病机制的理解不完整。
- 复发性GN相对罕见,决定了需要多中心研究来评估、检验和验证最新进展与疗法。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Recurrent glomerulonephritis (GN) is an important cause of kidney allograft failure, particularly in younger recipients. Approximately 15% of death-censored graft failures are due to recurrent GN, but this incidence is likely an underestimation of the magnitude of the problem. Overall, 18% to 22% of kidney allografts are lost due to GN, either recurrent or presumed de novo. The impact of recurrent GN on allograft survival was recognized from the earliest times in kidney transplantation. However, progress in this area has been slow, and our understanding of GN recurrence remains limited, in large part due to incomplete understanding of the pathogenesis of these diseases. This review focuses on recent advances in our general understanding of the pathophysiology of primary GN, the risk of recurrence in the allograft, and the consequences for kidney graft survival. We focus specifically on the most common forms of primary GN, including focal segmental glomerulosclerosis, membranous nephropathy, membranoproliferative glomerulonephritis, and IgA nephropathy. New understanding of the pathogenesis of these diseases has had direct clinical implications for transplantation, allowing better identification of candidates at high risk of recurrence and earlier diagnoses, and it is expected to lead to significance improvements in the therapy and perhaps even prevention of GN recurrence. More than ever, it is essential to fully characterize GN before transplantation as this information will direct our management posttransplantation. Further, the relative rarity of recurrent GN dictates the need for multicenter studies in order to evaluate, test, and validate recent advances and therapies.
引用
- Cosio FG, Cattran DC. Recent advances in our understanding of recurrent primary glomerulonephritis after kidney transplantation. Kidney Int. 2016. PMID: 27837947. doi:10.1016/j.kint.2016.08.030
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。